Hepatitis B and C

This information is useful for children, adults, and older adults
.
Why Yale Medicine?
  • Largest program for treating viral hepatitis in the area.
  • Our doctors are committed to providing individualized care for patients.
  • We use state-of-the-art techniques such as FibroScan and liver elastography.

Hepatitis B and C are common blood-borne viral infections that primarily affect the liver. About 350 million people are infected with hepatitis B across the globe, and there are about 1.5 million cases in the United States. 

Worldwide, about 170 million people have hepatitis C, while about 5 million Americans are infected. It is the leading cause of liver cirrhosis and liver transplants in the United States. Hepatitis B and C are known as silent killers because the diseases develop very slowly over many years, and thus most patients have no symptoms and don’t even know they are infected.

"We are the largest hepatitis treatment and clinical trials center in the region and serve as the primary referral center for Connecticut and southern New England for primary care, gastroenterology, infectious diseases, and other specialty providers who wish to refer both routine and complex cases of viral hepatitis," said Joseph Lim, MD, director of the Yale Medicine Viral Hepatitis Program

Clinical Trials

New treatments for many conditions are tested in clinical trials, which ultimately bring lifesaving new drugs and devices to the patients who need them most. By participating in a clinical trial, you may get access to the most advanced treatments for your condition, and help determine their benefits for future patients.